OL-053 Screening and identification of genes trans-regulated by HCV p7 protein with microarray assay  by Guo, J. et al.
Free Paper Presentations S53
March 2005 until March 2008. The samples tested for HCV-
Ab by using ELISA methods and reactive samples retested
in duplicate manner and repeatedly reactive samples
conﬁrmed by RIBA methods. All data analyzed in SPSS
software.
We found that 1.587%, 0.862% and 0.499% respectively of
blood donors were repeatedly reactive for HCV-Ab. The
conﬁrmatory result in the same period were: 0.311%, 0.314%
and 0.294% respectively. The repeatedly reactive samples
were signiﬁcantly reduced after change the screening kit.
Our ﬁndings showed that HCV prevalence was less than
some of other regions in our country and some neighbor’s
prevalence. Our strategy in reducing HCV prevalence such
as donor selection and educational program was great
effective and meet our goal in enhancing blood safety.
Establishment that strategy for other centers in our province
recommended.
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Introduction: Hepatitis C virus (HCV) is a major cause
of chronic hepatitis, liver cirrhosis, and hepatocellular
carcinoma throughout the world. Although HCV cannot
be incubated efﬁciently in vitro, several of its key
features have been elucidated in the past few years. HCV,
cloned successfully via molecule biological technology, is
an enveloped, positive single-stranded RNA (9.6-kb) virus
belonging to the Flaviviridae. The HCV genome has only one
ORF which is ﬂanked by a 5 and 3 noncoding region. The ORF
encodes for a large polyprotein precursor of about 3 000
amino acid residues, and this precursor protein is cleaved
by the host and viral proteinases to generate at least
10 proteins in the following order: NH2-C-E1-E2-p7-NS2-
NS3-NS4A-NS4B-NS5A-NS5B- COOH. HCV proteins not only
function in viral replication but also affect a variety of
cellular functions. HCV p7, which is located between the
E2 and NS2 proteins, is a 63 residue peptide encoded by
HCV genome between 2 580 2 768 nt. Although there are
studies on the genomic structure, synthesis and function of
p7 protein, the role of the HCV p7 protein in the virus life
cycle is not known. To gain more information on the HCV
p7 protein, and provide some new clues for elucidating the
potential biological function of p7, we use cDNA microarray
technique to screen genes regulated by p7.
Method: To investigate the biological functions of
hepatitis C virus p7, and to use cDNA microarray technique
to screen genes regulated by p7. The HCV p7 coding DNA
fragment was ampliﬁed with polymerase chain reaction
(PCR) technique by using PBRTM plasmid containing the
full length of HCV genome as the template. The expressive
vector of pcDNA3.1-p7 was constructed by routine molecular
biological methods. The HepG2 cells were transfected by
pcDNA3.1( ) and pcDNA3.1-p7, respectively using FuGENE6
transfection Reagent. The total RNA was isolated and re-
verse transcribed. The cDNAs were subjected for microarray
screening with 1152 cDNA probes. The expressive vector
has been constructed and conﬁrmed by restriction enzyme
digestion and DNA sequencing analysis. High quality mRNA
and cDNA had been prepared and successful microarray
screening had been conducted. From the scanning results,
it was found 1 genes were up-regulated and 22 genes were
down-regulated by p7 protein of HCV. HCV p7 protein is a
trans-regulator. The expression of p7 protein affected the
expression spectrum of HCV infected hepatocyte.
Results: See Figures 1 and 2, and table 1.
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Fig. 1. Products of pcDNA3.1( )-p7 PCR and restriction
enzyme cleaved were electrophoresed in 1.0% agarose
gel. Lane 1: EcoRI/BamHI cleaved; M: DNA Marker
(15,000+2,000 bp).
Fig. 2. Structure of expression plasmid pcDNA3.1( )-p7.
Table 1. Trans-regulated genes by HCV p7
Accession
number
Protein Cy3/
Cy5
NM_000553 Werner syndrome (WRN) 0.337
NM_002514 Nephroblastoma overexpressed gene (NOV), mRNA 0.368
AY142112 Anion exchanger SLC4A3 0.394
NM_001122 Adipose differentiation-related protein (ADFP) 0.403
AB028641 SOX11 0.406
NM_002804 Proteasome (prosome, macropain) 26S subunit,
ATPase, 3 (PSMC3)
0.410
AF123320 Lymphocyte activation-associated protein 0.411
NM_015150 Raft-linking protein (RAFTLIN) 0.411
AK131542 Moderately similar to renal tumor antigen 0.405
BC052628 Armadillo repeat containing, X-linked 2 0.419
AB020706 KIAA0899 protein 0.436
NM_015270 Adenylate cyclase 6 (ADCY6) 0.436
NM_005746 Pre-B-cell colony enhancing factor 1 (PBEF1) 0.448
NM_173631 Zinc ﬁnger protein 547 (ZNF547) 0.459
BC046099 TAF15 RNA polymerase II, TATA box binding protein
(TBP)-associated factor
0.473
AF370457 Ovarian epithelial carcinoma-related protein 0.476
NM_015568 PPP1R16B 0.483
NM_003419 ZNF345 0.485
NM_003260 transducin-like enhancer of split 2 (TLE2) 0.492
BC033522 p65 0.481
AK128380 FLJ46523 0.492
BX537378 C21orf4 0.469
NM_183419 RNF19 2.100
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Conclusions: HCV p7 protein is a trans-regulator. The
expression of p7 protein affected the expression spectrum
of HCV infected hepatocyte.
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Introduction: Patients who have undergone kidney
transplantation (TX) and suffer from hepatic C related
(HCV) cannot be treated with standard therapy (PEG-
IFN combined with ribavirin) due to acute rejection
risk. Furthermore, immuno-suppressive therapy facilitates
progression and infection and chronic hepatopathesis.
Monocytes and macrophages are known to produce extra-
hepatic breeding sites and spread disease. Our aim was
to lower macrophages, granulocytes, monocytes, pro-
inﬂammatory cells and viremia levels using an extra-
corporeal device:Adacolumn® (Otsuka).
Methods: The Adacolumn ﬁlter is ﬁlled with 2mm cellulose
acetate beads immersed in sterile saline solution. These
carriers absorb granulocytes and monocytes/macrophages
through FCR receptors. Six patients were treated in our
department. All patients were affected by virale genotype
1b. Inclusion criteria: kidney transplant at under one year
and HCV-RNA >800,000 copies. Patients underwent ﬁve
1-hour treatments for ﬁve consecutive days according to
protocol. Kidney and hepatic parameters were evaluated as
were changes in immuno-modulation (CD4, CD8) and HCV-
RNA base quantities, at end of treatment and at 1 month,
2 month and 3 month follow ups.
Results: During treatment cycles and successive follow ups
we observed a stabilization of kidney parameters and a non
signiﬁcant decrease in transaminase levels. At 3rd month
follow up we observed a signiﬁcant decrease in plasma
HCV-RNA in 3 patients (p < 0.01) associated with attenuation
of inﬂammatory phase (p < 0.2) and variations in immuno-
modulation. Only one patient presented altered CD4+ and
CD8+ where positive was observed at 3rd month. In another
patient, even though immuno- modulation improved, there
was no reduction in viremia.
Conclusions: The treatment was found to be safe without
hemodynamic or infective complications. Considering the
results this method should be used on a greater number of
patients evaluating successive treatment times in case of
viremia increase.
